Amgen

Amgen

Yahoo Finance • 14 hours ago

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren's disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful impro... Full story

Yahoo Finance • 19 hours ago

Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?

Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body w... Full story

Yahoo Finance • yesterday

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According... Full story

Yahoo Finance • 3 days ago

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market's view of the two companies has changed sharply. Since mid-2024, Novo's stock has fallen roughl... Full story

Yahoo Finance • 4 days ago

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid art... Full story

Yahoo Finance • 4 days ago

How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a... Full story

Yahoo Finance • 5 days ago

Barron's 400 ETF (BFOR) Adds Energy and Materials, Reduces Utilities and Consumer Discretionary in Fall Rebalance

DENVER, September 24, 2026--(BUSINESS WIRE)--The Barron's 400 ETF (NYSE Arca: BFOR, the "Fund"), a smart beta exchange-traded fund, has completed its semi-annual rebalance following the reconstitution and equal weighting of its underlying... Full story

Yahoo Finance • 5 days ago

UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities

Company Logo UPLIZNA growth is driven by new indications, global expansion, strong efficacy, differentiated CD19 targeting and twice-yearly dosing, though competition is intensifying. Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "UPLIZNA S... Full story

Yahoo Finance • 6 days ago

Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva

With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to r... Full story

Yahoo Finance • 6 days ago

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough The... Full story

Yahoo Finance • 7 days ago

Stock Market Today: Dow Skids As Trump Threatens Iran; Apple Nears Buy Point (Live Coverage)

Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point. Continue Reading... Full story

Yahoo Finance • 7 days ago

Stock Market Today: Dow Slips But Apple Touches A Buy Point; Homebuilder, Retailer Funds Shine (Live Coverage)

Stock Market Today: The Dow Jones index reversed lower despite new U.S.-Iran peace hopes. Apple stock is trading near a buy point. Continue Reading... Full story

Yahoo Finance • 8 days ago

Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan

Veeva Systems VEEV recently announced that Amgen AMGN has selected its Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it... Full story

Yahoo Finance • 8 days ago

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokima... Full story

Yahoo Finance • 8 days ago

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di... Full story

Yahoo Finance • 8 days ago

The Zacks Analyst Blog Highlights AMD, Linde, Amgen and INNOVATE

For Immediate Release Chicago, IL – September 21, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financi... Full story

Yahoo Finance • 9 days ago

The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule for Wegovy and Ozempic, generates roughly 75% of 2026 revenue. Morgan Stanley models that it will still represent... Full story

Yahoo Finance • 10 days ago

Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?

Quick Read Amgen (AMGN) yields 2.6% with a $10.08 annualized payout, topping Merck (MRK) at 2.29%, and has raised its dividend 6% annually versus Merck's smaller step-ups. Amgen's 17 billion-dollar products and $3.5B quarterly free cash f... Full story

Yahoo Finance • 11 days ago

Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks

Amgen's updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research high... Full story

Yahoo Finance • 11 days ago

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

Amgen (AMGN) closed the most recent trading day at $385.65, moving +1.55% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.17%. Meanwhile, the Dow lost 0.18%, and the Nasdaq, a tech-heavy index, added 0.4... Full story